Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The company's products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. Its clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase (TVT-058), a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a collaboration agreement with PharmaKrysto Limited for the pre-clinical activities associated with the cystinuria program. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Period	TotalRevenue
2015-12-31	$99.89M
2016-12-31	$133.59M
2017-12-31	$154.94M
2018-12-31	$164.25M
2019-12-31	$175.34M
2020-12-31	$198.32M
2021-12-31	$227.49M
2022-12-31	$109.46M
2023-12-31	$145.24M
2024-12-31	$233.18M

	A	B	C	D
1	Symbol	Price	Change	Volume
2	TVTX	$30.44	+0.00%	1.15M
3
4
5

Travere Therapeutics Inc. (TVTX) Revenue History

Revenue Data

Get Travere Therapeutics Inc. Data in Excel

More TVTX Financial Data